HIGHLIGHTS
- who: Sergey V. Kulemzin et al. from the Institute of Molecular and Cellular Biology, Siberian Branch of Russian Academy of Sciences have published the article: VH3-53/66-Class RBD-Specific Human Monoclonal Antibody iB20 Displays Cross-Neutralizing Activity against Emerging SARS-CoV-2 Lineages, in the Journal: (JOURNAL)
SUMMARY
Antibodies preventing cellular entry of SARS-CoV-2 are considered pivotal in protective immunity against coronavirus infection. The lack of effective virus-targeting therapies has spurred massive efforts to identify and extensively characterize potent neutralizing monoclonal_antibodies as a measure to counteract the COVID . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.